Caltrate

Phase 1Small molecule

SSecond Affiliated Hospital of Wenzhou Medical University

Caltrate is one of 49 small molecule programs targeting Vitamin D Deficiency. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Vitamin D DeficiencyActive, not recruiting

Ulcerative ColitisActive, not recruiting

Vitamin D DeficiencyPhase 1

Active, not recruiting

Ulcerative ColitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

460 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

Tremfya

Johnson & Johnson

Phase 3

2 2

Orencia

Bristol-Myers Squibb

Phase 3

1 3

Pulmicort

SSalix

Phase 3

3 4

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

3 5

Mesalazine

Ferring

Phase 3

17 6

Purinethol

SStason

Phase 3

1 7

IV Golimumab

Merck & Co.

Phase 3

1 8

Propionyl-L-Carnitine

LLee's Pharmaceutical Limited

Phase 3

3 9

Simponi

Remicade

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Caltrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Caltrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Caltrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Affiliated Hospital of Wenzhou Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSecond Affiliated Hospital of Wenzhou Medical University

Caltrate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Vitamin D Deficiency1 trial

Crohn's Disease1 trial

Ulcerative Colitis1 trial

References

Drug Info

Quick Facts

Related News